Page 8 - Maureen Testoni News Today : Breaking News, Live Updates & Top Stories | Vimarsana

First published on UPDATE: May 21, 2021: On Thursday, drugmaker Eli Lilly filed a motion in an Indiana district court to halt 340B-related monetary penalties, three days after the Biden administration set a June 1 deadline for pharmaceutical companies to comply with new conditions in the drug discount program and allow hospital pharmacies access to discounted drugs. The suit alleges a Monday letter from Diana Espinosa, acting head of the Health Resources and Services Administration, gives "no legal explanation or justification for the arbitrary June 1 deadline." Lilly filed an almost identica...

HRSA takes action against drug manufacturers that block drug discounts Published Wednesday, May. 19, 2021, 9:15 am Join AFP's 100,000+ followers on Facebook Purchase a subscription to AFP Subscribe to AFP podcasts on iTunes and Spotify News, press releases, letters to the editor: augustafreepress2@gmail.com (© BillionPhotos.com – stock.adobe.com) The Health Resources and Services Administration is taking action against pharmaceutical manufacturers that refuse to provide rural healthcare providers with discounted prescription drugs. The 340B Drug Pricing Program has a demonstrated record ...

Dive Brief: The U.S. Department of Health and Human Services has called out six pharmaceutical companies for violating rules under the 340B drug discount program, ordering them to repay affected healthcare providers for previous overcharges and warning of more penalties if they don't comply. Last July, some drugmakers stopped giving the 340B "ceiling" price — the maximum they can charge — on products sold to covered entities and dispensed through contract pharmacies. Others limited sales by requiring specific data or selling products only after a covered provider demonstrated 340B compl...

Dive Brief: HHS' Health Resources and Services Administration called out six pharmaceutical companies Tuesday for violating rules under the 340B drug discount program, ordering them to repay affected providers for previous overcharges and warning of more penalties if they don't comply. In July 2020 some drugmakers stopped giving the 340B ceiling price on their products sold to covered entities and dispensed through contract pharmacies, while others limited sales by requiring specific data or selling products only after a covered entity demonstrated 340B compliance, according to HRSA. In lette...

Photo: Jeff Lagasse/Healthcare Finance News Six drugmakers who have violated the 340B statute should immediately begin offering drugs at discounted prices to hospitals participating in the federal drug-pricing program, according to a letter sent to the drugmakers this week from the Health Resources and Services  Administration. The HRSA maintained that the drug manufacturers in question – AstraZeneca, Eli Lilly, Novartis, Novo Nordisk, Sanofi and United Therapeutics – placed restrictions on the 340B program for hospitals that dispense drugs through contract pharmacies, and these restrict...